FMR LLC 13D and 13G filings for Allogene Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-03-07 10:01 am Sale | 2025-02-28 | 13G | Allogene Therapeutics, Inc. ALLO | FMR LLC | 10,225,851 4.900% | -13,546,144 (-56.98%) | Filing |
| 2025-02-12 09:16 am Sale | 2024-12-31 | 13G | Allogene Therapeutics, Inc. ALLO | FMR LLC | 23,771,995 11.300% | -1,469,504 (-5.82%) | Filing |
| 2024-02-09 08:35 am Purchase | 2024-02-08 | 13G | Allogene Therapeutics, Inc. ALLO | FMR LLC | 25,241,499 14.999% | 323,544 (+1.30%) | Filing |
| 2023-07-10 10:20 am Purchase | 2023-07-07 | 13G | Allogene Therapeutics, Inc. ALLO | FMR LLC | 24,917,955 17.085% | 24,917,955 (New Position) | Filing |